Keyphrases
Anti-CTLA-4
42%
Blood Samples
14%
Cancer Types
14%
CD11b+
71%
CD247
14%
CD33
100%
Cellular Level
14%
Clinical Response
14%
Clinical Significance
100%
Clinical Status
14%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
14%
Disease Outcome
14%
Flow Cytometry
14%
Healthy Donors
28%
HLA-DR
71%
Immune System
14%
Ipilimumab
100%
Kaplan-Meier
14%
Lactate Dehydrogenase
14%
Log-rank Test
14%
Long-term Survival
14%
Median Survival
14%
Melanoma
28%
Monitoring Biomarker
14%
Monitoring System
14%
Myeloid Cells
100%
Myeloid-derived Suppressor Cells
100%
Overall Survival
28%
Patient Response
14%
Patient Survival
14%
Peripheral Blood
14%
Poor Survival
14%
Predictive Biomarker
14%
Predictive Impact
14%
Prognostic Biomarker
14%
Response Predictors
14%
Stage IV Melanoma
100%
System Monitoring
14%
T Cells
14%
Medicine and Dentistry
Biological Marker
28%
Cancer Types
14%
Clinical Significance
100%
CTLA-4
14%
Disease
14%
Flow Cytometry
14%
Immune System
14%
Ipilimumab
100%
Lactate Dehydrogenase
14%
Log Rank Test
14%
Long Term Survival
14%
Melanoma
100%
Myeloid Cell
100%
Myeloid-Derived Suppressor Cell
100%
Overall Survival
28%
T Cell
14%
Immunology and Microbiology
CD247
14%
CD33
100%
Cell Level
14%
CTLA-4
14%
HLA-DR
71%
Immune System
14%
Ipilimumab
100%
Long Term Survival
14%
Myeloid
100%
Myeloid-Derived Suppressor Cell
100%
Overall Survival
28%
Prognostic Biomarker
14%
T Cell
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
40%
Cytotoxic T Lymphocyte Antigen 4
80%
Disease
20%
Flow Cytometry
20%
Ipilimumab
100%
Lactate Dehydrogenase
20%
Long Term Survival
20%
Malignant Neoplasm
20%
Melanoma
100%
Overall Survival
40%